Table 3. Selected clinical trials targeting PD-(L)1 and CTLA-4 in NSCLC.
| NCT number with references | Design | ORR (%) | PFS (months) | OS (months) |
|---|---|---|---|---|
| Selected clinical trials with results | ||||
| NCT01673867 (195) | Nivolumab vs. docetaxel | 19 vs. 12 | 2.3 vs. 4.2 | 12.2 vs. 9.4 |
| NCT01642004 (209) | Nivolumab vs. docetaxel | 20 vs. 9 | 3.5 vs.2.8 | 9.2 vs. 6.0 |
| NCT02477826 (205) | Nivolumab plus ipilimumab vs. chemotherapy in lung cancer with a high TMB | 45.3 vs. 26.9 | 4.9 vs. 5.5; 7.2 vs. 5.5 (high TMB); 3.2 vs. 5.5 (low TMB) | NR |
| NCT01905657 (210) | Pembrolizumab (2 mg/kg) vs. docetaxel; pembrolizumab (10 mg/kg) vs. docetaxel | 30 vs. 8; 29 vs. 8 | 3.9 vs.4.0; 4.0 vs. 4.0 | 10.4 vs. 8.5; 12.7 vs. 8.5 |
| NCT02220894 (211) | Pembrolizumab vs. chemotherapy | 27 vs. 27 | 5.4 vs. 6.5 | 16.7 vs. 12.1 |
| NCT02578680 (200) | Pembrolizumab plus chemotherapy vs. placebo | 47.6 vs. 18.9 | 8.8 vs. 4.9 | NR vs. 11.3 |
| NCT01903993 (198) | Atezolizumab vs. docetaxel | 15 vs. 15 | 2.7 vs. 3.0 | 12.6 vs. 9.7 |
| NCT02008227 (199) | Atezolizumab vs. docetaxel | 52 vs. 18 | 2.8 vs. 4.0 | 13.8 vs. 9.6 |
| NCT02125461 (201,202) | Durvalumab vs. placebo in non-disease progression patients after platinum-based therapy | 28.4 vs. 16.0 | 16.8 vs. 5.6 | NR vs. 28.7 |
| NCT02395172 (203) | Avelumab vs. docetaxel in patients after platinum-based therapy | 15 vs. 11; 19 vs. 12 (PD-1+) | 2.8 vs. 4.2; 3.4 vs. 4.1 (PD-1+) | 11.4 vs. 10.3 |
| Selected ongoing clinical trials | ||||
| NCT03001882 | Nivolumab plus ipilimumab | |||
| NCT02659059 | Nivolumab plus ipilimumab vs. nivolumab plus ipilimumab and chemotherapy | |||
| NCT02477826 | Nivolumab plus ipilimumab vs. nivolumab plus ipilimumab and platinum-doublet chemotherapy | |||
| NCT02352948 | Durvalumab plus tremelimumab vs. durvalumab | |||
PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; CTLA-4, cytotoxic T-lymphocyte antigen-4; NSCLC, non-small-cell lung cancer; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; TMB, tumor mutational burden; NR, not recorded.